Metabolic Dysfunction-Associated Steatohepatitis (MASH)
video
MASLD in Diabetes: What Clinicians Should Know
"There is a significant interplay between type 2 diabetes and MASLD," explains Sobia Laique, MD, of Cleveland Clinic. Thorough screening is important to identify at-risk MASH in patients with diabetes.(3:23)
Lean MASH Patients Face Higher Mortality and Worse Outcomes
These data confirm that lean patients with MASH may be at greater risk of poor health outcomes than non-lean patients with MASH.
MASLD Clinical Outcomes: Numerous, Dangerous
Data on clinical outcomes in MASLD are lacking. This study鈥檚 goal was to provide a comprehensive meta-analysis of the longitudinal outcomes associated with MASLD.
In MASLD, Which Serum Lipid-Soluble Micronutrients Heighten Risk?
Serum lipid-soluble micronutrients, such as 25(OH)D and carotenoids, may be protective in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), whereas tocopherols may be associated with pathology, according to this report.
.jpg)
Q&A: Christos S. Mantzoros, MD, PhD, Discusses Steatotic Liver Disease
Christos S. Mantzoros, MD, DSc, PhD, professor of medicine at Harvard Medical School and Boston University, answers our questions about changes in the way we approach steatotic liver disease, formerly known as fatty liver disease.
Screening For MASH: How Accurate Are Non-Invasive Tests?
Investigators reported on the clinical utility of several non-invasive screening methods to reduce the burden of invasive liver tissue sampling in patients at risk of MASH.
Assessing MASH Risk in Older Adults with Diabetes
Patients over age 50 with type 2 diabetes are at particular risk for metabolic dysfunction-associated steatohepatitis, according to the results of this study.
MASLD in Lean Patients: What do We Know?
This systematic review of the literature provides an interpretation of the new criteria related to lean MASLD.